Barclays Bullish on 4D Molecular Therapeutics, Sees M&A and Pricing Trends as Key Catalysts
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.